RedHill Biopharma Terminates License Agreement For Aemcolo, A Treatment For Traveler's Diarrhea, Will Be Officially Terminated On October 8, 2024
RedHill Biopharma Terminates License Agreement For Aemcolo, A Treatment For Traveler's Diarrhea, Will Be Officially Terminated On October 8, 2024
redhill biopharma终止Aemcolo的授权协议，用于治疗旅行者腹泻，将于2024年10月8日正式终止。
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the mutual decision with Cosmo Technologies Ltd. ("Cosmo") to voluntary terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea (the "License Agreement"). The License Agreement, initially dated October 17, 2019, will be officially terminated on October 8, 2024.
RedHill生物制药有限公司（纳斯达克：RDHL）（“RedHill” 或 “本公司”），一家专业的生物制药公司，今日宣布与Cosmo Technologies Ltd.（“Cosmo”）共同决定自愿终止他们的Aemcolo独占性美国许可协议，该协议是治疗旅行者腹泻的协议（“许可协议”）。 最初于2019年10月17日签订的许可协议将于2024年10月8日正式终止。